Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory

Aims Retrospective review of neuroendocrine tumors (NETs) treated within the Australian Capital Territory to describe the local epidemiology and assess prognostic clinicopathological factors. Methods Patients with histologically proven non‐pulmonary low to intermediate grade NETs were identified fro...

Full description

Saved in:
Bibliographic Details
Published in:Asia-Pacific journal of clinical oncology 2016-03, Vol.12 (1), p.e133-e140
Main Authors: Malik, Laeeq, Chua, Yu Jo, Butt, Nadeem S, Yip, Desmond
Format: Article
Language:English
Subjects:
Adult
Aged
Australian Capital Territory - epidemiology
Biomarkers, Tumor - analysis
chromogranin A
Diagnosis
Epidemiology
Female
Humans
Ileum
Jejunum
Male
Medical prognosis
Metastases
Middle Aged
Neuroendocrine tumors
Neuroendocrine Tumors - epidemiology
Neuroendocrine Tumors - pathology
Pancreas
Patients
Prognosis
prognostic factors
Rectum
Retrospective Studies
Survival
Survival analysis
Survival Rate
Territory
Urine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Retrospective review of neuroendocrine tumors (NETs) treated within the Australian Capital Territory to describe the local epidemiology and assess prognostic clinicopathological factors. Methods Patients with histologically proven non‐pulmonary low to intermediate grade NETs were identified from our hospital clinical database. Data were analyzed according to epidemiological, clinical and histopathological characteristics. Results Of the 107 included patients, the most common primary tumor site was jejunum/ileum (32%), followed by rectum (22%) and pancreas (11.2%). In total, 32% had distant metastases at presentation, most commonly in the liver. Most patients were symptomatic at diagnosis, while 22.4% of cases were found incidentally. Second malignancies, in particular of gastrointestinal origin, were diagnosed in 33.6%. Surgical debulking was the most common treatment (59.8%) while 18% had multimodality therapy. With a median follow‐up of 25 months from diagnosis, about 78% of patients are still alive. Median time to first relapse was 15 months and the 5‐year survival rate was 80% for NETs of jejunum/ileum. Univariate survival analysis revealed tumor location, high Ki67 index, raised plasma chromogranin A, and urine 5‐hydroxyindoleacetic acid upon diagnosis to be associated with shorter 5‐year survival. Conclusion The epidemiologic characteristics and long‐term outcome in our series are comparable to other reported studies. This analysis presents some important prognostic factors which could be used for risk stratification in patients with NETs.
ISSN:1743-7555
1743-7563
DOI:10.1111/ajco.12121